Findings
Coordination challenges with multiple locations in DCTs.
Variability in data collection across decentralized locations and remote tools.
Challenges in implementing certain statistical approaches in DCTs.
Need for DHTs to be accessible and suitable for all trial participants.
Ensuring compliance with local laws and regulations.

Recommendations
Develop clear protocols for integrating decentralized elements into clinical trials, specifying remote and in-person activities.
Use digital health technologies (DHTs) and electronic systems to streamline data acquisition, informed consent, and investigational product tracking.
Provide training for all stakeholders, including trial personnel, local health care providers, and participants, on decentralized processes.
Implement robust safety monitoring plans to address adverse events in decentralized settings.
Ensure compliance with local and international laws governing telehealth, data privacy, and investigational product use.

Regulatory Considerations
Maintain compliance with FDA requirements under 21 CFR parts 312 and 812 for drug and device trials, respectively.
Document all trial activities and data flows in trial protocols and data management plans, ensuring traceability and integrity.
Ensure informed consent processes meet FDA standards and provide clear communication to participants about decentralized trial activities and data handling.
Address investigational product accountability by documenting IP distribution, storage, and return or disposal.
Design electronic systems for decentralized trials to comply with 21 CFR part 11 requirements for data reliability, security, and confidentiality.

Findings
The field lacks a centralized, standardized database of validated digital health technologies, making it difficult for researchers and clinicians to select appropriate tools.
Non-wearable sensors and software applications are the most common types of DHTs, with 83% of ambient technologies categorized as software or applications.
Most DHTs focus on mild cognitive impairment (MCI) and early Alzheimer’s disease, with fewer technologies validated for moderate or severe dementia stages.
Uneven Distribution of Dementia Subtypes – The review identified a gap in DHT validation for frontotemporal dementia (FTD) and Lewy Body dementia, with Alzheimer’s disease being the predominant focus.

Recommendations
Expand and maintain an open-access database of validated DHTs to improve accessibility and standardization.
Increase research on digital measures applicable to moderate and severe stages of dementia, as well as non-Alzheimer’s dementias.
Promote integration of wearable, ambient, and cognitive assessment tools to generate comprehensive digital phenotypes of patients.
Follow clear guidelines for analytical and clinical validation of DHTs to improve regulatory acceptance and research applicability.
Conduct more usability and feasibility assessments, especially for populations with cognitive decline, to ensure DHTs are accessible and effective in real-world settings.

Findings
The development of this standardized questionnaire highlights a critical gap in clinical research: the lack of a consistent method for collecting participant feedback. It implicitly finds that understanding the patient experience is essential for addressing issues like high dropout rates and patient burden. The tool's detailed sections suggest that factors from communication and scheduling to technology usability and visit burden are key determinants of a participant's trial experience.

Recommendations
The resource strongly recommends that sponsors and research sites proactively gather structured feedback directly from study participants. It advises using this tool to identify specific pain points in trial design and execution. The underlying recommendation is to adopt a more patient-centric and human-centered approach by integrating participant feedback into the continuous improvement of clinical trial protocols and operations, ultimately boosting recruitment and retention.

Regulatory Considerations
While not a formal regulatory guidance document, the tool supports the principles of patient-focused drug development (PFDD) encouraged by regulatory bodies like the FDA. Collecting data on the patient experience can help demonstrate that a trial's design and conduct minimizes undue burden and is ethically sound. This feedback can be a valuable component of submissions, illustrating a commitment to patient centricity and potentially improving the assessment of a trial's overall quality and integrity

Findings
Qualitative Methods: One-on-one interviews provide in-depth individual insights, while focus groups capture diverse perspectives through participant interaction.
Approaches such as Delphi panels and observational methods can complement interviews and focus groups in understanding patient experiences.
Quantitative Methods: Surveys provide structured, quantifiable data and are effective for large populations.
Careful design of questions and response options minimizes bias and improves data quality.
Mixed Methods:Combining qualitative and quantitative techniques enhances understanding and validates findings.
Sequential and concurrent designs can address complex research questions and improve robustness.
Barriers to Self-Report: Special adaptations may be needed for patients with disabilities, pediatric populations, or those with language or cultural differences.
Proxy reporting by caregivers is sometimes necessary but may introduce bias.
Social Media: Useful for real-time or retrospective insights into patient perspectives. Limitations include lack of verified identities and potential bias in user demographics.

Recommendations
Choose data collection methods aligned with research objectives and the target population.
Use open-ended questions for qualitative research to elicit unbiased responses; avoid leading or judgmental prompts.
Pilot test interview guides, surveys, and response options to ensure clarity and relevance.
Integrate cultural and linguistic adaptations for diverse populations in multinational studies.
For mixed-method research, establish clear objectives for combining qualitative and quantitative components and address conflicting findings systematically.

Regulatory Considerations
Data collected through qualitative or quantitative methods must meet regulatory standards for integrity and reliability when submitted to the FDA.
Screening and exit interviews should not interfere with the integrity of ongoing clinical trials; use trained third-party interviewers where appropriate.
Researchers should follow ethical standards and federal regulations when using social media data, ensuring informed consent and data privacy.

Findings
Research is more impactful and relevant when patients and other stakeholders are treated as equal partners throughout the entire study lifecycle.
A lack of shared vision, clear communication protocols, and defined roles are significant barriers to the success of multi-stakeholder research teams.
Engaging diverse stakeholders leads to the development of more patient-centered research questions and outcome measures that reflect real-world priorities.
Institutional barriers, such as inflexible policies on compensation and data access for non-researcher team members, frequently undermine effective collaboration.
Successful patient-centered outcomes research (PCOR) requires specific skills in collaborative problem-solving, conflict navigation, and leading productive team meetings.

Recommendations
Integrate patients, caregivers, clinicians, and other stakeholders into research teams from the initial planning stages to ensure alignment with patient needs.
Establish a shared vision and clear ground rules for communication, decision-making, and responsibilities to foster a cohesive and productive team environment.
Provide training and resources for all team members on best practices for stakeholder engagement, collaborative teamwork, and patient-centered research methods.
Institutions should develop supportive infrastructure, including fair compensation policies and streamlined onboarding processes, to facilitate meaningful stakeholder participation.
Research plans should be flexible, allowing teams to adapt their engagement strategies and methodologies in response to stakeholder feedback and changing circumstances.

Regulatory Considerations
Evidence generated through patient-centered outcomes research can strengthen regulatory submissions by demonstrating that a product's benefits are meaningful to patients.
The inclusion of diverse patient populations in research, a core tenet of PCOR, helps generate real-world evidence that is more generalizable and relevant for post-market surveillance.
Regulatory bodies are increasingly emphasizing the use of patient-experience data and patient-reported outcomes, which are central to the PCORI research model.
Engaging stakeholders in the selection of clinical trial endpoints helps ensure alignment with patient priorities, which can facilitate more efficient regulatory review.
The collaborative, transparent methods promoted by PCORI can help build trust and align expectations among researchers, patients, and regulatory agencies.

Findings
The CardiacSense PPG device can reliably detect heart rate in various situations, but noise suppression during activity remains a challenge.
The study did not directly address the device's ability to detect atrial fibrillation in ambulatory patients, indicating a gap in current research.
Further studies are needed to confirm the device's effectiveness in detecting AF during ambulatory conditions.

Recommendations
Improve noise suppression technology to enhance the device's accuracy during motion.
Conduct further studies to validate the device's ability to detect atrial fibrillation in ambulatory patients.
Continue research to address the limitations identified in the current study.

Regulatory Considerations
Adherence to FDA guidance for new medical device applications is crucial.
Ensure compliance with regulatory standards for digital health technologies.

Findings
Patient experience data encompass a range of inputs, including symptom burdens, treatment impacts, patient preferences, and views on unmet medical needs.
These data inform all stages of medical product development, from discovery to post-market use.
Quantitative methods (e.g., surveys) provide numerical insights, while qualitative methods (e.g., interviews) offer in-depth understanding. Mixed methods combine both for a fuller perspective.Social media and verified patient communities present novel data collection opportunities but require consideration of verification and representativeness challenges.
Probability sampling (e.g., stratified random sampling) is emphasized for generalizability, while non-probability methods (e.g., convenience sampling) are useful for exploratory research. Representativeness ensures that patient input reflects the diversity and heterogeneity of the target population.
Data collection should adhere to good clinical practices and regulatory standards.
Research protocols should address missing data, quality assurance, and confidentiality.
Early collaboration with the FDA is recommended to align on study designs and regulatory requirements.

Recommendations
Define clear research objectives and determine specific research questions before selecting data collection methods.
Use probability sampling methods whenever feasible to ensure representativeness of the target population.
Address data quality through rigorous planning, data management, and adherence to FDA-supported standards.
Incorporate diverse perspectives by including underrepresented patient populations, tailoring methods to specific subgroups as needed.
Leverage existing data sources, such as patient registries and literature, to complement primary data collection efforts.

Regulatory Considerations
Data submitted to FDA should include clear documentation of the study protocol, intended use, and data collection methodologies.
Researchers must comply with human subject protection regulations (e.g., 21 CFR Parts 50 and 56) and good clinical practice guidelines.
For data intended to support regulatory submissions, adherence to FDA-supported data standards (e.g., CDISC) is strongly encouraged.
Missing data should be addressed through pre-planned strategies and summarized in the study report.
Patient experience data must meet methodological rigor to ensure their reliability and relevance for regulatory decision-making.